Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Catalyst Pharmaceuticals, Inc. - Common Stock (NQ:CPRX)

21.33 +0.05 (+0.23%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Catalyst Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Why NASDAQ:CPRX Is a Promising High-Growth Stock in the Midst of Consolidation.
Based on a technical and fundamental analysis of NASDAQ:CPRX we can say: CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX), a strong growth stock, setting up for a breakout. 
Via Chartmill
NASDAQ:CPRX: good value for what you're paying.
Uncover the potential of CATALYST PHARMACEUTICALS INC, an undervalued stock. NASDAQ:CPRX maintains a strong financial position and offers an appealing valuation. 
Via Chartmill
This Expand Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
 
Via Benzinga
Beyond The Numbers: 6 Analysts Discuss Catalyst Pharmaceuticals Stock
 
Via Benzinga
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2025 List of America's Most Successful Mid-Cap Companies
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Unlocking the Growth Potential of NASDAQ:CPRX.
Exploring CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX)'s CANSLIM characteristics. 
Via Chartmill
Why NASDAQ:CPRX qualifies as a high growth stock.
Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) qualifies as a high growth stock. 
Via Chartmill
Exploring the Growth Potential of NASDAQ:CPRX as It Nears a Breakout.
Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) Is a Standout High-Growth Stock in a Consolidation Phase. 
Via Chartmill
While growth is established for NASDAQ:CPRX, the stock's valuation remains reasonable.
Investors seeking growth at a reasonable cost should explore CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX). 
Via Chartmill
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Unlocking the high Growth Potential of NASDAQ:CPRX.
Delving into CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX)'s high Growth Prospects. 
Via Chartmill
BeiGene Stock Meets 80-Plus RS Rating Benchmark
One key metric to look for in a stock is an 80-plus Relative Strength Rating. BeiGene stock just hit that mark, with a jump to 84 Wednesday. 
Via Investor's Business Daily
NASDAQ:CPRX, an undervalued stock with good fundamentals.
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
Via Chartmill
NASDAQ:CPRX, a growth stock which is not overvalued.
NASDAQ:CPRX is not too expensive for the growth it is showing. 
Via Chartmill
Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) qualifies as a high growth stock.
Why the growth investor may take a look at CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX). 
Via Chartmill
Should you consider NASDAQ:CPRX for growth investing?
Exploring growth characteristics of CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX). 
Via Chartmill
BridgeBio Pharma Stock Earns 87 RS Rating
BridgeBio Pharma stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an increase from 64 to 87. 
Via Investor's Business Daily
SpringWorks Therapeutics Stock Sees RS Rating Jump To 86
On Monday, SpringWorks Therapeutics stock hit a key technical milestone, seeing its Relative Strength Rating jump to 86. 
Via Investor's Business Daily
Catalyst Pharmaceuticals Settles Patent Litigation Case With Teva Pharmaceutical
Catalyst Pharmaceuticals settles patent litigation with Teva, delaying generic Firdapse launch until 2035. Legal actions against other defendants remain ongoing. 
Via Benzinga
Topics Intellectual Property
IBD Tech Leader Catalyst Rockets After Striking A Key Deal With Teva
One of Catalyst's key products has protection against a knockoff from Teva until 2035. 
Via Investor's Business Daily
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals
As Part of the Settlement, Teva Receives a License to Market Generic FIRDAPSE Beginning in February 2035 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) qualifies as a high growth stock.
Why the high growth investor may take a look at CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX). 
Via Chartmill
Unlocking the Growth Potential of NASDAQ:CPRX.
Exploring CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX)'s growth characteristics. 
Via Chartmill
Arcellx Stock Earns 82 Relative Strength Rating
Arcellx stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 79 to 82. 
Via Investor's Business Daily
Neurocrine Biosciences Stock Sees RS Rating Upgrade
Neurocrine Biosciences stock saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 67 to 71. 
Via Investor's Business Daily
For those who appreciate value investing, NASDAQ:CPRX is a compelling option with its solid fundamentals.
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
Via Chartmill
Why NASDAQ:CPRX Is a Standout High-Growth Stock in a Consolidation Phase.
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX), a strong growth stock, setting up for a breakout. 
Via Chartmill
Catalyst Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
NewAmsterdam Pharma Stock Hits 90-Plus RS Rating
NewAmsterdam Pharma stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 74 to 95. 
Via Investor's Business Daily
Don't overlook NASDAQ:CPRX—a stock with solid growth prospects and a reasonable valuation.
Investors seeking growth at a reasonable cost should explore CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX). 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.